Harvard Eye Associates notes that FLIgHT, a femtosecond laser glaucoma procedure using imaging to guide a laser that creates tiny openings inside the eye, is still in FDA trials and not yet available
Public source
Publisher name
Public post
If you or someone you love has glaucoma, you know the routine. A row of drop bottles on the kitchen table, yellow cap, purple cap, gray cap, and the daily worry about a…
Company
Harvard Eye Associates
For over 50 years, we have brought our patients the most advanced treatments in both medical and surgical eye care.
- Industry
- Medical Practices
- Location
- Laguna Hills, US
- Company size
- 51–200 employees
About Harvard Eye Associates
Book Appointment: phreesia.me/HEASchedulingLink For over fifty years, we have brought our patients the most advanced treatments and procedures in both medical and surgical eye care. Our board-certified physicians have extensive training and experience in each of their specialties and have performed a combined total of over 200,000 surgical procedures. Our physicians have published dozens of original research articles and have given many academic lectures internationally at annual meetings. Harvard Eye Associates continues to conduct research on new lens implants, surgical devices, and medications before they are available to the general medical community. Our surgeons serve as Medical Advisory Board members to a number of health care technology companies.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
California LASIK & Eye
California LASIK & Eye research highlights the MIT photonics platform concept of an intraocular lens that could become part of an augmented-reality display system.
Research & Knowledge
Duke Eye Center
Duke Eye Center researchers presented groundbreaking work spanning glaucoma, retinal disease, lens biology, ocular aging, and regenerative medicine at the XXVIIth Biennial Meeting of the International Society for Eye Research in Valencia, Spain.
Research & Knowledge
Wilmer Eye Institute, Johns Hopkins Medicine
Wilmer Eye Institute, Johns Hopkins Medicine published a new study led by Cindy Cai suggesting that semaglutide and other GLP-1 drugs do not statistically change the risk of developing neovascular age-related macular degeneration.
Research & Knowledge
Cleveland Sight Center
Cleveland Sight Center is conducting a trial to see if cellular-rejuvenation therapy will reverse age-related diseases like glaucoma after 30 years of research and hard work.
Research & Knowledge
Helix Surgical